LONDON – Immuno-oncology specialist Iteos Therapeutics Inc. raised $125 million in the second tranche of its series B, bringing the total for the round to $175 million and fueling clinical development of a pipeline of drugs targeting PD-1 resistance.
Kendall Square was a great jumping-off point for Cambridge, Mass.’s Pandion Therapeutics Inc. but with an $80 million series B in its pocket, the time has come to pick up sticks to accommodate its growth.
The allure of gene therapy was proved yet again as Waltham, Mass.-based Affinia Therapeutics Inc. bagged an oversubscribed $60 million series A financing to boost the push for drugs to benefit people affected by muscle and central nervous system conditions.
LONDON – AM-Pharma BV raised a further $52 million for the phase III trial of its recombinant alkaline phosphatase product, Recap, in treating sepsis-associated acute kidney injury (AKI), but now faces a delay in starting the study, as the COVID-19 crisis takes up more and more clinical resources.
Cambridge, Mass.-based Elevatebio LLC has triple-pronged plans for its $170 million series B round, which the company said will be directed toward manufacturing cell and gene therapies, enabling new technology platforms, and pursuing therapeutics.
HONG KONG – Chinese biopharmaceutical company Abbisko Therapeutics Co. Ltd., of Shanghai, defied turbulent stock markets amid the COVID-19 pandemic to snag $70 million in its latest round of financing.
RSS
